Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018
Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection on Undiagnosed Atrial Fibrillation
JAMA 320:146-155,139, Steinhubl, S.R.,et al, 2018
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke
Stroke 47:2380-2385, Yong, J.H.E.,et al, 2016
Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
NEJM 373:823-833, Douketis,J.D.,et al, 2015
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation
Stroke 42:112-118, Mercaldi,C.J.,et al, 2011
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
Transoesophageal Echocardiography in Patients with Acute Stroke with Sinus Rhythm and No Cardiac Disease History
JNNP 81:412-415, Cho,H.-J., et al, 2010
10-Year Stroke Prevention After Successful Carotid Endarterectomy for Asymptomatic Stenosis (ACST-1): A Multicentre Randomised Trial
Lancet 376:1074-1084, Halliday,A.,et al, 2010
Cost-Effectiveness of Preventive Treatment of Intracranial Aneurysms: New Data and Uncertainties
Neurol 73:258-265,254, Greving,J.P.,et al, 2009
Medical (Nonsurgical) Intervention Alone Is Now Best for Prevention of Stroke Associated With Asymptomatic Severe Carotid Stenosis
Stroke 40:e573-e583, Abbott,A., 2009
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)
Stroke 39:1482-1486,1406, Healey,J.S.,et al, 2008
Exposure to Antipsychotics and Risk of Stroke: Self Controlled Case Series Study
BMJ 337:616-618,586, Douglas,I.J. &Smeeth,L., 2008
Warfarin Versus Aspirin for Stroke Prevention in an Elderly Community Population With Atrial Fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A Randomised Controlled Trial
Lancet 370:493-503,460, Mant,J.,et al, 2007
Effect of Urgent Treatment of Transient Ischaemic Attack and Minor Stroke on Early Recurrent Stroke (EXPRESS Study): A Prospective Population-Baed Sequential Comparison
Lancet 370:1432-1442,1398, Rothwell,P.M., et al, 2007
Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
JAMA 293:699-706, OBrien,C.L. &Gage,B.F., 2005
Adding Aspirin to Clopidogrel After TIA and Ischemic Stroke
Neurol 64:1117-1121, Hankey,G.J. &Eikelboom,J.W., 2005
A Risk Score for Predicting Stroke or Death in Individuals with New-Onset Atrial Fibrillation in the Community
JAMA 290:1049-1056,1093, Wang,T.J.,et al, 2003
Stroke Prevention in Atrial Fibrillation
JAMA 290:1093-1095, Waldo,A.L., 2003
Emergent Use of Anticoagulation for Treatment of Patients with Ischemic Stroke
Stroke 33:856-861, Adams,H.P., 2002
Carotid Stenting and Endarterectomy
Stroke 33:1063-1070, Gray,W.A.,et al, 2002
Blood Pressure Control in Stroke Patients
Neurol 59:23-25, Messerli,F.H.,et al, 2002
Warfarin Therapy for an Octogenarian who has Atrial Fibrillation
Ann Int Med 134:465-474, Gage,B.F.,et al, 2001
Risk, Causes, and Prevention of Ischaemic Stroke in Elderly Patients with Symptomatic Internal-Carotid-Artery Stenosis
Lancet 357:1154-1160,1142, Alamowitch,S.,et al, 2001
Endovascular Treatment of Symptomatic Carotid Stenosis Using Stent Placement
Stroke 32:1855-1859, Dietz,A.,et al, 2001
AGGRENOX: A Combination of Antiplatelet Drugs for Stroke Prevention
The Medical Letter 442:11-12, , 2000
Aspirin for the Primary Prevention of Stroke and Other Major Vascular Events
ArchNeurol 57:326-332,306, Hart,R.G.,et al, 2000
Low Molecular-Weight Heparin Versus Aspirin in Patients With Acute Ischaemic Stroke and Atrial Fibrillation: A Double-Blind Randomised Study
Lancet 355:1205-1210, Berge,E.,et al, 2000
Thienopyridines or Aspirin to Prevent Stroke and Other Serious Vascular Events in patients at High Risk of Vascular Disease?
Stroke 31:1779-1784, Hankey,G.J. et al, 2000
Cost-Effectiveness of New Antiplatelet Regimens Used as Secondary Prevention of Stroke or Transient Ischemic Attack
Arch Int Med 160:2773-2778, Sarasin,F.P.,et al, 2000
Therapeutic Benefit, Aspirin Revisited in Light of the Introduction of Clopidogrel
Stroke 30:1716-1721, Gorelick,P.B.,et al, 1999
The North American Symptomatic Carotid Endarterectomy Trial, Surgical Results in 1415 Patients
Stroke 30:1751-1758,1745, Ferguson,G.G.,et al, 1999
Treatment and Secondary Prevention of Stroke:Evidence, Costs, and Effects on Individuals and Populations
Lancet 354:1457-1463, Hankey,G.J.&Warlow,C.P., 1999
Antithrombotic Therapy to Prevent Stroke in Patients with Atrial Fibrillation:A Meta-Analysis
Ann Int Med 131:492-501,537, Hart,R.G.,et al, 1999
Cost-Effectiveness of Anticoagulation in Nonrheumatic A Fib in the Primary Prevention of Ischemic Stroke
Stroke 29:1827-1832, Lightowlers,S.&McGuire,A., 1998
The Antiplatelet Effects of Ticlopidine and Clopidogrel
Ann Int Med 129:394-405, Sharis,P.J.,et al, 1998
Cost-Effectiveness of Screening for Carotid Stenosis in Asymptomatic Persons
Ann Int med 126:337-346, Lee,T.T.,et al, 1997
Assessment of the Efficacy of Noninvasive Screening for Patients with Asymptomatic Neck Bruits
Stroke 28:1330-1339, Obuchowski,N.A.,et al, 1997